Literature DB >> 12113033

Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention.

Y Shiratori1, H Yoshida, M Omata.   

Abstract

Since the major causes of hepatocellular carcinoma are hepatitis viruses, the difference and similarity of clinical features in relation to the causative virus may indicate that persistent inflammation of the liver is a major role in hepatocellular carcinoma development in both HBV and HCV infection. However, there is a variety of molecular products of virus-inducing mutagenesis, especially in HBV. An advance in the diagnosis of hepatocellular carcinoma is imaging modality to detect hemodynamics of hepatocellular carcinoma with noninvasive methods of ultrasonography and tumor markers. Chemoprevention using synthetic retinoid is another important issue for the prevention of hepatocellular carcinoma development, as well as viral eradication and suppression of inflammation in the liver using interferon and other drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12113033     DOI: 10.1586/14737140.1.2.277

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  7 in total

1.  Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance.

Authors:  Zhi-Jun Zeng; Lian-Yue Yang; Xiang Ding; Wei Wang
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

2.  Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up.

Authors:  Naveen Ballem; Eren Berber; Tracy Pitt; Allan Siperstein
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

3.  Effects of Zhaoyangwan on chronic hepatitis B and posthepatic cirrhosis.

Authors:  Cui-Ping Zhang; Zi-Bin Tian; Xi-Shuang Liu; Qing-Xi Zhao; Jun Wu; Yong-Xin Liang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

4.  Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.

Authors:  Long Lv; Ping Wang; Xiaoqing Zhou; Beicheng Sun
Journal:  Tumour Biol       Date:  2013-04-06

5.  Branched-chain amino acids to tyrosine ratio value as a potential prognostic factor for hepatocellular carcinoma.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

6.  Outcome of combined hepatocellular and cholangiocarcinoma of the liver.

Authors:  Jue Wang; Fenwei Wang; Anne Kessinger
Journal:  J Oncol       Date:  2010-09-02       Impact factor: 4.375

7.  DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC.

Authors:  Yasuteru Kondo; Tatsuki Morosawa; Soichiro Minami; Yasuhito Tanaka
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.